DOI: https://doi.org/10.24959/cphj.20.1540

Evaluation of the effect of the combination of glucosamine derivatives with quercetin on the morphofunctional state of the thymus and spleen of rats under the toxic effect of doxorubicin

K. V. Vietrova, T. S. Sakharova

Abstract


In the rating of the most used antineoplastic drugs, the antibiotic of the anthracycline series doxorubicin occupies a significant place. The introduction of doxorubicin into clinical practice has made it possible to improve the current and delayed results of treatment; however, the non-selective spectrum of its cytostatic action is manifested by a number of drug-dependent side effects, among them cardio- and myelotoxicities are the most characteristic ones. Among the modern and proven approaches to the pharmacocorrection of the organotoxic effect of doxorubicin, it is considered traditional to carry out the supporting therapy using drugs of various pharmacotherapeutic groups, which action is directed to the corresponding affected organ/target system. A significant disadvantage of this approach is the creation of prerequisites for polypharmacy and, consequently, all the negative consequences of its use. Currently, scientific data on the prospects of searching for products of the supporting therapy among biologically active substances of natural origin and their combinations characterized by a universal multicomponent mechanism of the cytocorrective action, pronounced therapeutic effectiveness and a high safety profile continue to appear.

Aim. To study the combination of glucosamine derivatives with quercetin as a potential сorrector of the immunotoxic action of doxorubicin in the experiment in rats.

Materials and methods. The study in evaluating the corrective effect of the combination of glucosamine derivatives with quercetin under conditions of doxorubicin intoxication was performed on 75 rats. To simulate intoxication, experimental animals (excluding the intact group) were injected intraperitoneally with doxorubicin in the dose of 5 mg/kg of the body weight once a week for four weeks. The combination under research was administered once daily intragastrically for 28 days after the first injection of the cytostatic. The histomorphological studies of the thymus and spleen were performed using standard methods of light microscopy.

Results. In the course of the study, it was shown that under the effect of the combination of glucosamine derivatives with quercetin studied a decrease in dystrophic changes in the thymus and spleen of rats was observed, the intensity of regeneration processes increased, indicating the restoration of the functional state of immunocompetent organs. By the severity of the protective effect the combination studied was superior to monocomponent reference samples of glucosamine hydrochloride and quercetin.

Conclusions. The combination of glucosamine derivatives with quercetin has a corrective effect on the state of the organs of immunogenesis (thymus and spleen) under conditions of the development of doxorubicin intoxication in rats and is a promising subject for further pharmacological study as a modifier of the immunosuppressive effect of doxorubicin.

Keywords


quercetin; glucosamine hydrochloride; N-acetylglucosamine; doxorubicin; immunosuppression; cytoprotective action

References


Benjanuwattra, Ju., Siri-Angkul, N., Chattipakorn, S. C., Chattipakorn, Nipon. (2020). Doxorubicin and its proarrhythmic effects: A comprehensive review of the evidence from experimental and clinical studies. Pharmacological Research, 151, 104542. https://doi.org/10.1016/j.phrs.2019.104542

Yu, X., Ruan, Ya., Huang, X., Dou, L., Lan, M., Cui, J. et al. (2020). Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochemical and Biophysical Research Communications, 523, 1, 140-146. https://doi.org/10.1016/j.bbrc.2019.12.027

Prasanna, P. L., Renu, K., Gopalakrishnan, A. V. (2020). New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sciences, 250, 117599. doi: https://doi.org/10.1016/j.lfs.2020.117599

Shebeko, S. K. (2017). Klinichna farmatsiia, 21 (4), 17–21. doi: https://doi.org/10.24959/cphj.17.1445

Hajra, S., Patra, A. R., Basu, A., Bhattacharya, S. (2018). Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: Effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation. Biomedicine & Pharmacotherapy, 101, 228-243. https://doi.org/10.1016/j.biopha.2018.02.088

Moskvichev, E. P., Rozhkovskii, Ya. V. (2014). Svіt meditcini ta bіologії, 3 (45), 129–133. Available at: https://womab.com.ua/smb-2014-03/4390

Zupanets, K. O. (2011). Eksperymentalne obgruntuvannia kombinovanoho zastosuvannia pokhidnykh hliukozaminu z kvertsetynom pry riznykh variantakh perebihu osteoartrytu. Extended abstract of candidate’s thesis. Kharkiv, 25. Available at: http://dspace.nuph.edu.ua/handle/123456789/574

Mousavi, S. H., Bakhtiari, E., Hosseini, A., Jamialahmadi, Kh. (2018). Protective effects of glucosamine and its acetylated derivative on serum/glucose deprivation-induced PC12 cells death: Role of reactive oxygen species. Research in Pharmaceutical Sciences, 13 (2), 121-129. doi: https://doi.org/10.4103/1735-5362.223794

Hezaveh, Z. S., Azarkeivan, A., Janani, L., Shidfar, F. (2019). Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine: A double-blind randomized clinical trial. Journal of Research in Medical Sciences, 24, 91. doi: https://doi.org/10.4103/jrms.JRMS_911_18

Guide for the care and use of laboratory animals. (2011). (8th ed.). Washington: The National Academies Press, 246.

Directive (EU) 2010/63/EU of the European Parliament and of the Council of 22 September 2010 On the Protection of Animals Used for Scientific Purposes. (2010). Official J. of the European Union, 276 (53), 33–79. Available at: http://data.europa.eu/eli/dir/2010/63/oj

Trofimova, T. S. (2008). Eksperymentalni doslidzhennia efektyvnosti tiotryazolinu za umov doksorubitsynovoi kardiomiopatii. Candidate’s thesis. Odesa, 155.

Zupanets, I. A. (1993). Eksperimentalnoe obosnovanie ispolzovaniia gliukozamina i ego proizvodnykh v meditcine. Doctor’s thesis. Kupavna, 90.

Afanasev, Yu. I. et al. (2013). Gistologiia, embriologiia, tcitologiia. (6th ed.). Moscow: GEOTAR-Media, 800.

Aruin, L. I. et al. (1987). Strukturnye osnovy adaptatcii i kompensatcii narushennykh funktcіi. D. S. Sarkisova (Ed.). Moscow: Meditcina, 445.

Pakrishen, S. V., Mokhort, M. A. (2013). Suchasni problemy toksikolohii, 1/2, 81-85. Available at: http://protox.medved.kiev.ua/index.php/ua/issues/2013/1-2/item/64-toxicodynamics-of-doxorubicin-morphological-study

Tuliakov, V. O., Zupanets, K. O., Shebeko, S. K. (2009). Farmakolohiia ta likarska toksikolohiia, 2, 3-8.

Zupanets, I. A., Sakharova, T. S., Vietrova, K. V., Zupanets, K. O. (2015). Vestnik farmatsii, 1 (67), 83-88. Available at: https://elib.vsmu.by/123/5722

Rykalo, N. A., Huminska, O. Yu. (2015). Visnyk Vinnytskoho natsionalnoho medychnoho universytetu, 19 (1), 70-73. Available at: https://www.vnmu.edu.ua/downloads/pdf/visnik2015-19-1.pdf


GOST Style Citations


1.   Doxorubicin and its proarrhythmic effects : а comprehensive review of the evidence from experimental and clinical studies / J. Benjanuwattra et al. Pharmacological Research. 2020. Vol. 151. P. 104542. DOI: https://doi.org/10.1016/j.phrs.2019.104542

 

2.   Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes / X. Yu et al. Biochemical and Biophysical Research Communications. 2020. Vol. 523, Iss. 1. P. 140–146. DOI: https://doi.org/10.1016/j.bbrc.2019.12.027

 

3.   Prasanna P., Renu K., Gopalakrishnan A. V. New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sciences. 2020. Vol. 250. P. 117599. DOI: https://doi.org/10.1016/j.lfs.2020.117599

 

4.   Шебеко С. К. Дослідження впливу комбінації кверцетину з похідними глюкозаміну на перебіг мембранозного ураження нирок в експерименті. Клінічна фармація. 2017. Vol. 21, № 4. P. 17–21. DOI: https://doi.org/10.24959/cphj.17.1445

 

5.   Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: Effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation / S. Hajra et al. Biomedicine & Pharmacotherapy. 2018. Vol. 101. P. 228–243. DOI: https://doi.org/10.1016/j.biopha.2018.02.088

 

6.   Москвичёв Е. П., Рожковский Я. В. Влияние иммунотропных препаратов на активность мембранных ферментов лимфоцитов в условиях курсового введения доксорубицина. Світ медицини та біології. 2014. № 3 (45). C. 129–133. URL: https://womab.com.ua/smb-2014-03/4390

 

7.   Зупанець К. О. Експериментальне обґрунтування комбінованого застосування похідних глюкозаміну з кверцетином при різних варіантах перебігу остеоартриту : автореф. дис. … канд. фармац. наук : 14.03.05. Харків, 2011. 25 с. URL: http://dspace.nuph.edu.ua/handle/123456789/574

 

8.   Protective effects of glucosamine and its acetylated derivative on serum/glucose deprivation-induced PC12 cells death : role of reactive oxygen species / S. H. Mousavi et al. Research in Pharmaceutical Sciences. 2018. Vol. 13, Iss. 2. P. 121–129. DOI: https://doi.org/10.4103/1735-5362.223794

 

9.   Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine : а double-blind randomized clinical trial / Z. S. Hezaveh et al. Journal of Research in Medical Sciences. 2019. Vol. 24. P. 91. DOI: https://doi.org/10.4103/jrms.JRMS_911_18

 

10. Guide for the care and use of laboratory animals. 8-th ed. Washington : The National Academies Press, 2011. 246 p.

 

11. Directive (EU) 2010/63/EU of the European Parliament and of the Council of 22 September 2010 On the Protection of Animals Used for Scientific Purposes. Official J. of the European Union. 2010. L. 276, Vol. 53. P. 33–79. URL: http://data.europa.eu/eli/dir/2010/63/oj

 

12. Трофімова Т. С. Експериментальні дослідження ефективності тіотриазоліну за умов доксорубіцинової кардіоміопатії : дис. … канд. мед. наук : 14.03.05. Одеса, 2008. 155 с.

 

13. Зупанец И. А. Экспериментальное обоснование использования глюкозамина и его производных в медицине : дис. ... д-ра мед. наук (в форме научного доклада). Купавна, 1993. 90 с.

 

14. Гистология, эмбриология, цитология : учебник / Ю. И. Афанасьев, и др. ; под ред. Ю. И. Афанасьева, Н. А. Юриной. 6-е изд., перераб. и доп. Москва : ГЭОТАР-Медиа, 2013. 800 с.

 

15. Структурные основы адаптации и компенсации нарушенных функций : руководство / Л. И. Аруин и др. ; под ред. Д. С. Саркисова. Москва : Медицина, 1987. 445 с.

 

16. Пакришень С. В., Мохорт М. А. Токсикодинаміка доксорубіцину (морфологічне дослідження). Сучасні проблеми токсикології. 2013. № 1-2. С. 81–85. URL: http://protox.medved.kiev.ua/index.php/ua/issues/2013/1-2/item/64-toxicodynamics-of-doxorubicin-morphological-study

 

17. Туляков В. О., Зупанець К. О., Шебеко С. К. Фармакологічні властивості глюкозаміну : мембраностабілізуючі, протизапальні, антиоксидантні і імунотропні. Фармакологія та лікарська токсикологія. 2009. № 2. С. 3–8.

 

18. Изучение влияния производных глюкозамина на доксорубицин-индуцированную гибель клеток в эксперименте / И. А. Зупанец и др. Вестник фармации. 2015. № 1 (67). С. 83–88. URL: https://elib.vsmu.by/123/5722

 

19. Рикало Н. А., Гумінська О. Ю. Особливості стану імунітету статевонезрілих щурів на тлі хронічного рифампіцин-ізоніазид індукованого гепатиту, їх кореляції з показниками клітинного циклу тимусу та селезінки. Вісник Вінницького національного медичного університету. 2015. Т. 19, № 1. С. 70–73. URL: https://www.vnmu.edu.ua/downloads/pdf/visnik2015-19-1.pdf





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Clin. pharm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)